US 10543179

US Patent 10,543,179 — Summary

Core bibliographic data

Sources: Google Patents (https://patents.google.com/patent/US10543179/en); DrugPatentWatch (https://www.drugpatentwatch.com/p/patent/10543179).

Abstract (verbatim)

"The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg."

What the invention is

The patent claims a prophylactic method-of-treatment protocol for relapsing-remitting multiple sclerosis (RRMS) built around the oral S1P receptor modulator fingolimod (FTY720; marketed as Gilenya®). The specification explains that fingolimod treatment can be associated with adverse events (e.g., transient bradycardia/AV block at initiation, infections, macular edema, liver enzyme elevation) and that the claimed regimen manages a specific infection risk — varicella zoster virus (VZV / chickenpox) — by screening and vaccinating before starting the 0.5 mg daily oral dose.

Claims

There is one independent claim (claim 1) and three dependent claims (claims 2–4). Plain-language overview:

• Claim 1 (independent): A method of treating RRMS in a patient in need, comprising three sequential steps: (a) identify a patient at risk of VZV infection by testing for a history of VZV infection; (b) vaccinate that at-risk patient against VZV; and (c) administer orally fingolimod (or a pharmaceutically acceptable salt) at a daily dosage of 0.5 mg — thereby limiting the risk of VZV infection. Essentially: test for chickenpox immunity → vaccinate if susceptible → then start 0.5 mg/day fingolimod.
• Claim 2 (dependent): The method of claim 1, wherein "treating" includes reducing the frequency of clinical exacerbations.
• Claim 3 (dependent): The method of claim 1, wherein fingolimod is administered as the hydrochloride salt (i.e., as marketed Gilenya).
• Claim 4 (dependent): The method of claim 1, wherein the infection is chickenpox.

Source: DrugPatentWatch claims listing (https://www.drugpatentwatch.com/p/patent-claims/10543179); the claim text is corroborated by the D. Del. claim-construction opinion in Novartis Pharm. Corp. v. HEC Pharm Co., No. 1:20-cv-00133 (https://www.ded.uscourts.gov/sites/ded/files/opinions/20-133.pdf).

Litigation context (including CAFC 2026 search)

• The '179 patent has been asserted in multiple Hatch-Waxman (ANDA) suits against generic fingolimod filers (chiefly HEC Pharm and related entities) in the District of Delaware (e.g., 1:20-cv-00133, 1:21-cv-01530, 1:22-cv-00352, 1:23-cv-00026, 1:21-cv-00645) and the Northern District of California (3:21-cv-03397 / 5:21-cv-03397), per the Google Patents litigation metadata. Claim 1 is the asserted independent claim; the Delaware court construed the preamble as a limiting statement of purpose and the "thereby limiting" clause as a non-limiting statement of intended result.
• CAFC 2026 docket search: I found no CAFC 2026 docket entry specific to patent 10,543,179. The 2026 CAFC/Supreme Court activity reported in the news concerns a different Gilenya patent — US 9,187,405 (the 0.5 mg dosing-regimen patent), including the CAFC's invalidity ruling on the '405 patent and a June 2026 Supreme Court injunction reinstatement (https://pharmaphorum.com/news/supreme-court-throws-novartis-a-lifeline-for-gilenya-defense). Per your instruction not to conflate similar numbers, I am flagging that this is not the '179 patent. The most recent '179-specific activity I found is ongoing district court litigation (e.g., a September 12, 2025 briefing on obviousness summary judgment in D. Del. No. 1:20-cv-00133), not a 2026 CAFC docket.

Expiration caveat

• Google Patents lists "Anticipated expiration 2030-09-20," but search results contradict that: the FDA Orange Book lists 10,543,179 for Gilenya (NDA 022527) with a December 25, 2027 expiration, and multiple litigation summaries confirm a terminal disclaimer limits the term to no later than December 25, 2027 (https://www.docketalarm.com/FDA/Orange_Book/022527/GILENYA/). Per your rule to prefer live search results over training data, the operative expiration date is December 25, 2027.

Uncertainty note

I did not independently verify the full claim set against the USPTO PAIR/Patent Center record; the claim text above comes from DrugPatentWatch and court filings, which are consistent with each other and with the litigation record. The CAFC search was inconclusive for 2026 because no '179-specific CAFC docket surfaced — that absence is noted as a limitation, not a confirmation that none exists.

I'll search for litigation involving US patent 10543179 specifically, being careful not to conflate it with the similar-numbered Gilenya patents (e.g., US 9,187,405).

Let me search for the additional cases and recent status updates.

Let me search for the remaining Delaware and California cases specifically.

Litigation involving US Patent 10,543,179

Bottom line: Yes — the '179 patent has been litigated, but the activity is confined to Hatch-Waxman/ANDA and 505(b)(2) infringement suits filed by Novartis in two districts (D. Del. and N.D. Cal.). I found no CAFC appeal, no Supreme Court petition, and no PTAB proceeding specific to 10,543,179. Every case below names the '179 patent alongside its sister patent US 9,187,405 (the 0.5 mg "no-loading-dose" patent) — the two are asserted together, so any docket described as "Gilenya '405" activity must be checked to see whether '179 is also in play.

Data caveat: The 2026 "current date" in this task (April 26, 2026) is earlier than some search results I retrieved (e.g., a pharmaphorum piece dated 12 September 2026). Those future-dated items concern the '405 patent, not the '179 patent, and I flag the date inconsistency rather than rely on them. My '179-specific status data runs through September 2025 filings; I could not verify a trial verdict or final judgment on the '179 patent in 2026.

Case table

Sources: Google Patents litigation metadata (https://patents.google.com/patent/[US10543179](/patent/US10543179)/en); DrugPatentWatch patent-litigation page for 10,543,179 (https://www.drugpatentwatch.com/p/alphasignals/litigation/patent/10543179); DocketBird 1:22-cv-00352 (https://www.docketbird.com/court-cases/Novartis-Pharmaceuticals-Corporation-v-Handa-Neuroscience-LLC-et-al/ded-1:2022-cv-00352); Handa consent judgment (https://paragraphfour.com/wp-content/uploads/2014/05/dedc21cv0645CJ.pdf); IPWatchdog PTAB roundup (https://ipwatchdog.com/2021/05/12/ptab-filings-roundup-microsoft-battles-daedalus-blue-intel-gears-up-first-file-fight-electric-blanket-boogaloo/).

Case-by-case detail

1. Novartis Pharmaceuticals Corp. v. HEC Pharm Co., Ltd., D. Del. No. 1:20-cv-00133 — the flagship '179 case.
Filed the same day the '179 patent issued (Jan 28, 2020). The original complaint asserted the '179 patent against a broad set of ANDA filers (Apotex, Bionpharma, Emcure, Heritage, Ezra Ventures, Glenmark, HEC, Hetero, Prinston, Strides, Zydus/Cadila) in a suit reported at >$3 billion in controversy; Judge Leonard P. Stark issued an early opinion (reported as a 9-page ruling) on the injunction balance favoring Novartis (https://yur-gazeta.com/golovna/zastosovuyuchi-novyi-patent-novartis-blokue-generichni-versiyi-gilenya.html). The case was consolidated with the HEC '179 "Second Action" (1:21-cv-01530). As of the most recent filings I could retrieve:

• The court construed claim 1: the preamble ("A method for treating relapsing remitting multiple sclerosis in a patient in need thereof") is a limiting statement of purpose (and contemplates an efficacious purpose but not actual efficacy), and the "thereby limiting the risk of infection caused by varicella zoster virus" clause is a non-limiting statement of intended results. "Testing said patient for a history of infection caused by VZV" = checking for a history or evidence of prior infection or vaccination.
• Sept 12, 2025: Novartis's brief opposing defendants' summary-judgment motion on obviousness and Daubert motion to exclude Dr. Steinman (D.I. 441); Novartis also moved for partial summary judgment of no §101 ineligibility, no §102(f) derivation, and §271(e) infringement of the '179 patent (D.I. 384–387).
• The court docket is now captioned 1:20-cv-00133-JLH (Judge Jennifer L. Hall), having previously been -GBW (Williams) and -LPS (Stark).

Textbook of the merits: HEC's obviousness combination on the '179 is Kappos/Cohen 2010 + Berger 2009 + Harpaz 2008; Novartis rebuts with non-obviousness evidence (no public data linking fingolimod to VZV, alleged teaching-away from live vaccination, vaccine-efficacy concerns).

URLs: https://www.ded.uscourts.gov/sites/ded/files/opinions/20-133.pdf; https://www.courtlistener.com/docket/16769154/novartis-pharmaceuticals-corporation-v-hec-pharm-co-ltd/; complaint analysis https://ai-lab.exparte.com/case/dct/ded/1:20-cv-00133/doc/analysis/369.

2 & 3. Novartis v. Handa Neuroscience, LLC (D. Del. 1:21-cv-00645; N.D. Cal. 3:21-cv-03397 / 5:21-cv-03397).
Filed May 4, 2021 (Delaware) and two days later (the N.D. Cal. "safety suit"), asserting both the '405 and '179 patents against Handa's 505(b)(2) NDA No. 214962 (fingolimod lauryl sulfate ODT; "HND-020" / TASCENSO ODT). The court denied Handa's §1404/§1406 transfer and venue motions. The parties settled: a Consent Judgment and Order of Injunction was entered October 24, 2022; Handa stipulated that the asserted '405 and '179 claims are valid and infringed, took a license with a royalty on net sales, and all other claims/counterclaims were dismissed with prejudice. Case terminated 2022-10-26. Handa's public filings confirm it paid only its own legal fees and no settlement payment to Novartis (https://www.honsec.com.tw/uploads/underWriting/2202_4.pdf; https://news.gbimonthly.com/tw/invest/show.php?num=53907).

4, 5, 6 (1:21-cv-01530, 1:22-cv-00352, 1:23-cv-00026).
These appear in the consolidated/related-case record. 1:21-cv-01530 is plead as the "Second Action" in the HEC consolidated case. 1:22-cv-00352 was the Handa follow-on in D. Del., where the court denied Handa's motion for judgment on the pleadings seeking §101 invalidity, holding the claims "appear to be directed to a method of treating multiple sclerosis in certain patients by administration of a specific amount of a specific compound (fingolimod)… not a patent ineligible natural phenomenon" (citing Vanda v. West-Ward). I could not independently verify the filing date or disposition of 1:23-cv-00026 beyond its appearance in the patent's litigation metadata.

What did not happen on the '179 patent

• No CAFC appeal specific to 10,543,179 was found. The prominent Federal Circuit/Supreme Court activity in this estate — Novartis v. HEC Pharm / Accord Healthcare, Nos. 21-1070 and 22-671, culminating in the June 21, 2022 rehearing decision invalidating the '405 patent for inadequate written description — concerns US 9,187,405, not 10,543,179. Do not conflate the two.
• No PTAB proceeding (IPR/PGR) against 10,543,179 was found. (Consistent with the prior section.)
• No reexamination or district-court final judgment of invalidity on the '179 surfaced in my searches; Handa stipulated to validity in its consent judgment, and the HEC case was still pre-verdict on the '179 as of the last retrievable filings.

Limitations / things to verify

1. Current (2026) status of D. Del. 1:20-cv-00133 on the '179 patent was not confirmable — my newest '179-specific docket data is September 12, 2025 (summary-judgment briefing). A trial or ruling could have occurred afterward.
2. Exact filing dates/defendant rosters for 1:21-cv-01530, 1:23-cv-00026, and the N.D. Cal. case(s) were not fully verified; the N.D. Cal. docket appears under both 3:21-cv-03397 and 5:21-cv-03397 in the metadata, which I report literally rather than resolving.
3. Several 2026 news items about Gilenya generics (Supreme Court injunction, CAFC invalidity) concern the '405 patent, and some carry dates later than this task's April 26, 2026 cutoff; I flag these as (a) about a different patent and (b) date-inconsistent with the stated current date.
4. The most reliable sources for a definitive live check are PACER/CourtListener for D. Del. 1:20-cv-00133, 1:21-cv-00645, 1:21-cv-01530, 1:22-cv-00352, 1:23-cv-00026 and N.D. Cal. 3:21-cv-03397, and the patent's Google Patents litigation links (https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A21-cv-01530).

If you want, I can next pull the '179-specific docket entries in 1:20-cv-00133 (claim-construction order, the Sept 2025 MSJ/Daubert papers, and any 2026 trial/final-judgment entry) to pin down the current outcome.

Proceedings overview

Total AIA trial proceedings on file: 0 — no Inter Partes Reviews, Post-Grant Reviews, or Covered Business Method reviews have ever been filed against US 10543179 (breakdown: 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denied). The canonical USPTO Open Data Portal ingest shows no AIA trial proceedings for this patent, and independent web searching surfaced no older or recently-filed petitions that ODP has not yet indexed. Defensive posture: this patent is completely untested at the PTAB — every claim remains presumptively valid, no IPR-based estoppel exists against anyone, and a defendant facing assertion today must build invalidity from scratch in district court (or file its own IPR within the § 315(b) one-year window from service).

No proceedings to report

There are no individual proceedings to profile. I verified this three ways:

1. USPTO ODP (canonical source): the structured "PTAB proceedings on file" block reports no AIA trial proceedings for US 10543179 as of the most recent ingest.
2. Web search for the patent number + PTAB terms ("10543179" IPR, "10543179" final written decision, "10543179" institution): no PTAB petition, institution decision, or Final Written Decision referencing US 10543179 was found.
3. Search for fingolimod/Gilenya PTAB activity generally: the only PTAB proceedings that surfaced involve different Novartis Gilenya patents, not this one.

Important distinction: sister-patent IPRs are NOT this patent

Because the search results surfaced heavy PTAB activity on related Gilenya patents, and a defendant could be forgiven for conflating them, I want to flag explicitly that these are separate patents and separate proceedings:

• US 8,324,283 (fingolimod/mannitol solid formulation) — IPR petitions by Torrent, Apotex, and Mylan (filed 2014); all claims invalidated as obvious; affirmed by the Federal Circuit in Novartis AG v. Torrent Pharmaceuticals Ltd. (Apr. 12, 2017). Not US 10543179.
• US 9,187,405 (0.5 mg fingolimod daily dosing "absent an immediately preceding loading dose") — IPR by Apotex (filed 2017-02-03, joined by Sun, Teva/Actavis, Argentum); the Board sustained the claims (FWD 2018-07-11); CAFC initially affirmed (2022-01-04) but then reversed on rehearing (2022-06-21), holding the no-loading-dose limitation lacked written description. Novartis's cert petition followed. Not US 10543179.

US 10543179 is the later-issued continuation (application 15/986,992, filed 2018-05-23, granted 2020-01-28, priority 2009-09-29), listed in the Orange Book for Gilenya® (use code U-2719, expiry 2027-12-25 with pediatric exclusivity). The Taiwanese prospectus excerpt found in search describes it as covering treatment of MS patients at risk of varicella-zoster virus (VZV) infection with 0.5 mg fingolimod daily, consistent with the abstract's "testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod … at a daily dosage of 0.5 mg."

The patent has been asserted in Hatch-Waxman litigation — e.g., Novartis v. Handa Neuroscience LLC, D. Del. No. 1:21-cv-00645 (and related Delaware/N.D. Cal. cases 1:21-cv-01530, 1:22-cv-00352, 1:23-cv-00026, 1:20-cv-00133, 3:21-cv-03397 / 5:21-cv-03397 per the patent's own litigation metadata). Per the search result from Handa's Taiwan filings, Handa settled with Novartis on 2022-10-24, with Novartis withdrawing the infringement suits. But none of that district-court activity is a PTAB proceeding, and no ANDA filer appears to have ever petitioned the Board against the '179 patent.

Strategic summary

Claims status. Every claim of US 10543179 is UNTESTED at the PTAB. No claim has been canceled, and no claim has been sustained in an IPR. I deliberately do not recite claim numbers here: the claim text was not included in the materials provided to me, and I will not invent a claim count or numbering. What can be said with confidence is that the entire patent remains intact and in force (status: Active, anticipated expiration 2030-09-20 per Google Patents metadata, with Orange Book expiry 2027-12-25).

Estoppel landscape. Because no IPR has been filed, there is no § 315(e)(2) estoppel binding any party on any ground. For a defendant being asserted against today, all prior-art grounds remain available — anticipation and obviousness over any patent or printed publication, unconstrained by any Board record. The only relevant clock is § 315(b): if you have been served with a complaint alleging infringement of the '179 patent, you have one year from service to file an IPR petition. Given the patent's 2009 priority date, PGR is not available (the claims' effective filing date predates the AIA's March 16, 2013, threshold), so IPR is the only AIA vehicle.

Pattern signals. No repeat petitioner exists (zero petitions). No defensive aggregator (e.g., Unified Patents) appears in the chain for this patent. The pattern signal is contextual: the sister patents in the same Gilenya estate were heavily attacked — one fully invalidated at the PTAB ('283) and one invalidated by the CAFC on written-description grounds ('405) — and generic entry on 0.5 mg Gilenya was accelerated by those outcomes. The fact that the '179 continuation has nonetheless drawn zero PTAB challenges is itself telling: (i) it issued only in January 2020, after the most aggressive wave of fingolimod IPRs had already been filed and resolved against the earlier patents; (ii) most ANDA filers settled with Novartis (Handa's settlement 2022-10-24 being the last publicly surfaced); and (iii) with the foundational dosing-regimen patent ('405) now invalidated, challengers may view the '179 method-of-treatment claims as narrower and/or may have settled their way past the point of standing to challenge it.

Recommended next steps

• If you are a defendant asserting an invalidity defense in litigation: there is no PTAB FWD to lean on — do not cite one for this patent. The relevant precedent to study is the HEC Pharm line on the sibling '405 patent (Novartis Pharm. Corp. v. HEC Pharm Co., No. 21-1070, CAFC rehearing opinion of 2022-06-21, invalidating the no-loading-dose limitation for lack of written description) — but that holding is case-specific to the '405 claims and does not automatically extend to the '179 claims. If your demand letter cites the '179 patent, the correct play is a fresh § 103/§ 102 analysis on this patent's own claims, not borrowed IPR grounds.
• Check the § 315(b) clock immediately. If you are already sued and more than one year has passed since service, an IPR is barred; your invalidity fight stays in district court (clear-and-convincing standard). If you are pre-suit or recently served, an IPR petition is still viable and would be the first-ever PTAB test of this patent — the Board would be deciding these claims on a clean record.
• Monitor the active district-court docket (D. Del. 1:21-cv-00645 and related cases) for any re-assertion of the '179 patent against later ANDA filers. PTAB filings tend to follow new assertions — the absence of IPRs to date partly reflects the settlement-heavy posture of the Gilenya ANDA wars, which could change if a new filer refuses to settle.
• Verify the exact claim set before any filing. Obtain the '179 patent's claims from USPTO Patent Center (patent number 10543179, application 15/986,992) — the claim text was not available in the materials I was given, and claim-level strategy (independent vs. dependent, method steps, dosage + monitoring limitations) is the first thing to nail down.

Bottom line: no PTAB proceeding exists on US 10543179, so there is no PTAB-derived ammunition for or against it — but also no estoppel standing in your way. The patent is litigated but PTAB-virgin, and if you are within the § 315(b) window you would be the first challenger to test it.

Inventors

All eight named inventors (priority application 2009-09-29; issued patent 2020-01-28):

Unusual patterns: None. This is a routine in-house clinical-development inventorship group; there is no evidence of a mass inventor departure or a post-filing portfolio fire-sale. The inventors are the clinical/pharmacology team behind fingolimod (Gilenya) at Novartis.

Original assignee

• Entity on the issued patent: Novartis Pharmaceuticals Corp (the Google Patents header and DrugPatentWatch both list "Assignee: Novartis Pharmaceuticals Corp"; the US application US15/986,992 was filed 2018-05-23 in that name).
• Product: Yes — the patent is listed in the FDA Orange Book for GILENYA (fingolimod HCl), NDA 022527 (approved 2010-09-21), use code U-2719, with a listed expiry of Dec 25, 2027 (terminal disclaimer). The assignee manufactures and sells the claimed product.
• Line of business: Large-cap research-based pharmaceutical company (US subsidiary of Novartis AG).
• Current status: Operating. Novartis is actively enforcing the patent (see litigation below) and paid the 4th-year maintenance fee (12 Jul 2023).

Assignment timeline

I could not pull live reel/frame numbers from the USPTO Assignment Center in this session (https://assignmentcenter.uspto.gov/ could not be queried directly), so the entries below are reconstructed from the USPTO-derived legal-event feed on Google Patents, which indexes the same underlying assignment records. Do not treat the reel/frame fields as verified — they are marked as unknown rather than guessed.

• Executed date not shown / recorded 2019-12-18 — Reel unknown/unknown (USPTO-derived event on Google Patents)
  • Conveyance: Assignment of assignor's interest ("ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)")
  • Assignor: Novartis AG
  • Assignee: Novartis Pharmaceuticals Corporation
  • Correspondent: not retrievable from available records
  • Context: Internal consolidation — title to the US case moved from the Swiss parent (Novartis AG) into the US operating subsidiary (Novartis Pharmaceuticals Corp), the entity that would later sue. This is standard standing-perfecting practice for Hatch-Waxman litigation, not an arm's-length sale.

No other recorded assignments appear in the Google Patents/USPTO-derived legal events for this patent: no transfer to any LLC, no security agreement, no license, no merger, no change of name. If the Assignment Center is consistent with the event feed, Novartis Pharmaceuticals Corporation still owns the patent today — which is itself a finding (original operating assignee retained ownership).

Timeline diagram

timeline
    title Ownership of US 10543179
    2009 : Priority application filed
    2018 : US continuation filed
         : Filed by Novartis Pharms Corp
    2019 : Title consolidated from Novartis AG
    2020 : Patent issued Jan 28
         : First ANDA suit filed in Delaware
    2023 : Maintenance fee paid

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No transfer to any "IP / Licensing / Holdings / Ventures" LLC. The only recorded transfer is parent-to-subsidiary within the Novartis group (Novartis AG → Novartis Pharmaceuticals Corp, recorded 2019-12-18). Novartis Pharmaceuticals Corp is an operating company with a marketed product (Gilenya, NDA 022527).

2. Known asserter in the chain — not present. Neither Novartis AG nor Novartis Pharmaceuticals Corp appears on any public NPE/PAE list (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant, Vringo, Pendrell, Round Rock, etc.). The asserting entity is a top-tier operating pharmaceutical company.

3. Repeat correspondent across the chain — unclear / insufficient data. Only one recorded transfer was identified and its correspondent of record was not retrievable from the available sources, so recurrence cannot be assessed. No NPE-related correspondent pattern is evident.

4. Cascading transfers — not present. A single internal transfer, not a chain of chained LLC assignments.

5. Pre-litigation transfer — timing element present, NPE inference not supported. The Novartis AG → Novartis Pharmaceuticals Corp assignment was recorded 2019-12-18, roughly six weeks before the first suit (Novartis Pharms. Corp. v. HEC Pharm Co., 1:20-cv-00133, D. Del., filed 2020-01-28 — the same day the patent issued). However, this is an intra-Novatis consolidation into the entity that owns and sells the drug, not a transfer to a third-party asserter arranged for venue or standing games. This is the normal Hatch-Waxman practice of perfecting title in the US marketing entity before an ANDA suit.

6. Bankruptcy fire-sale — not present. Novartis has not undergone bankruptcy; no trustee or § 363 sale.

7. Privateering — not present. The patent never left the operating company; the assignee asserting it is the manufacturer itself.

8. Defensive aggregator (anti-NPE) — not present. The chain terminates at Novartis Pharmaceuticals Corp, an operating company; the patent has not been neutralized by RPX, AST, LOT, Unified Patents, or OIN — it is being actively asserted.

Verdict

Operating-company assertion

Novartis Pharmaceuticals Corporation — a large operating pharmaceutical company that manufactures and sells Gilenya (fingolimod HCl), the drug embodying the claims — owns and enforces US 10543179. The patent is Orange Book-listed for NDA 022527 (DrugPatentWatch/TheraRadar), and Novartis sued generic ANDA filers (HEC Pharm, Zydus/Cadila, GlaxoSmithKline, et al.) in Hatch-Waxman litigation beginning 2020-01-28 (Novartis Pharms. Corp. v. HEC Pharm Co., 1:20-cv-00133, D. Del.; claim-construction opinion available on CourtListener). The only recorded assignment is an internal Novartis AG → Novartis Pharmaceuticals Corp consolidation (recorded 2019-12-18, per the USPTO-derived legal-event feed), which is consistent with operating-company title management rather than any NPE pattern.

Verification links:

• USPTO Assignment Center: https://assignmentcenter.uspto.gov/ (search patent no. 10543179; reel/frame to be confirmed there — not retrievable in this session)
• Google Patents legal events: https://patents.google.com/patent/US10543179/en
• First infringement suit docket: https://www.courtlistener.com/docket/16769154/1/novartis-pharmaceuticals-corporation-v-hec-pharm-co-ltd/
• Orange Book listing: https://www.drugpatentwatch.com/p/patent/10543179

I'll search for the specific patent's prior-art citations and prosecution record.

Let me pull the front-page "References Cited" lists specifically.

Prior Art Analysis — US 10,543,179 B2 ("Dosage regimen of an S1P receptor modulator")

0. Data-source limitation (stated up front)

I was not able to retrieve the complete front-page "References Cited" list (the Form PTO-892 / patent face listing of U.S. patent documents and non-patent literature) for US 10,543,179. The Google Patents and Justia renderings available to me reproduce most of the "Other Publications" / non-patent-literature list and the "Cited By" (forward-citation) list, and the search index surfaced a large partial extract of the patent's own cited-publications block (patentimages.storage.googleapis.com/57/fe/21/91f6bb98e330a8/US10543179.pdf), but I could not obtain a verified, complete enumeration of the cited U.S. patent documents. Per the operating rules, I am flagging this as a limitation rather than filling the gap with invented citations. The one U.S. patent I can tie to this family with confidence is US 6,004,565 (Chiba), which appears as an IPR exhibit and is the foundational fingolimod patent; I do not represent that it is the only, or even necessarily a face-cited, reference.

Also note: this patent's own "Cited By" list (Argentum's WO2021158839–845 series and US 11,135,197 B2) is forward citation — later documents citing the '179 patent — and is therefore not prior art against it at all.

1. The controlling date, and why it guts half the cited list

The '179 patent's priority date is 29 September 2009 (Google Patents priority metadata; TheraRadar family 43759693; Honsec underwriting prospectus). US 15/986,992 was filed 23 May 2018 as a continuation; granted 28 January 2020. Because the claims are entitled to a 2009 effective filing date, pre-AIA 35 U.S.C. § 102/103 apply, and the critical date for § 102(a)/(b)/(e) art is 29 September 2009 (subject to any priority attack).

This matters enormously here, because a large fraction of the references printed on the face of the '179 patent post-date the priority date and are not § 102 prior art — they appear in the "Other Publications" block as examiner background/IDS citations, not as applied art. That category includes, at minimum:

Analyst caution: these references are frequently mis-cited as "the prior art against the '179 patent" because they appear in the patent's citation block. They are not available for § 102 or § 103 unless the priority claim is broken. This is also consistent with the Delaware record, where Novartis's expert (Dr. Steinman) emphasised that the "first normative data on the effect of fingolimod on immune response" and the Arvin VZV work did not appear until after the priority date (D. Del. 1:20-cv-00133, D.I. 441 at 4, re Steinman Rpt. ¶ 246; Arvin 2015).

2. Reference-by-reference inventory

Group A — Patent documents

Group B — Non-patent literature cited in prosecution with dates before the critical date (29 Sep 2009) — the operative art

Group C — Post-priority material in the same list (not §102 art — see §1 table)

Gershon 2010; Winkelmann 2011; Gelfand 2012; Jain & Bhatti 2012; Ontaneda 2012; Makri 2013; VARIVAX SmPC 2013; Tyler 2015; VARILRIX SmPC 2015; Lemtrada/Mavenclad/Mayzent labels; Mulero 2018; Arvin 2015 (Novartis's own VZV study, cited in the litigation record as unpublished until 2015). None of these can anticipate or support obviousness against claims entitled to the 2009 priority date.

Group D — Art that exists but was not applied to this patent

Kovarik/Thomson; Chiba/Kappos 2005/Budde; Kappos 2010 (NEJM 362(5):387–401, Feb 2010 — post-priority) — these are the Grounds 1–3 combinations from the Argentum IPR petition (Pet. 20779). See §4.

3. § 102 conclusion, element by element

No reference, alone or as cited on the face of the '179 patent, discloses all three steps of claim 1. Anticipation under § 102 requires a single reference disclosing every element, arranged as claimed (Net MoneyIN v. VeriSign). The claim-1 elements and the best single-reference hits are:

• Claim 1 — no anticipating reference identified. Every candidate either teaches the drug/dose but not the VZV protocol (Chiba, Kappos 2006, Budde, Cohen 2009), or teaches the VZV protocol but not the drug/dose (Harpaz 2008, Berger 2009, Garber 2008).
• Claim 2 (reducing frequency of clinical exacerbations) — the additional element is disclosed by Kappos 2006 and Cohen 2009 (ARR/relapse-rate reductions; TRANSFORMS). But because claim 2 incorporates all of claim 1, no reference anticipates claim 2 as a whole.
• Claim 3 (fingolimod hydrochloride salt) — the HCl form is disclosed in Chiba US 6,004,565 and throughout the Kappos/Budde fingolimod art. Element-level only.
• Claim 4 (the infection is chickenpox) — Garber 2008 discloses chickenpox specifically (varicella = chickenpox). Element-level only.

Bottom line on § 102: the cited prior art creates an element-level novelty attack against the individual steps, but not a single-reference anticipation of any issued claim. The genuine invalidity vector is § 103 (as the Examiner twice held, and as is being litigated in D. Del. 1:20-cv-00133).

4. Contradiction to flag against the earlier-generated sections

The previously generated "Obviousness" section states that its "IPR Ground 2" and "IPR Ground 3" (Kovarik+Thomson; Chiba+Kappos 2005+Budde; Kappos 2010) were asserted against this patent, and refers to "the IPR petition (Grounds 2–3)" for the '179 patent. That attribution is incorrect and should be corrected:

1. The previously generated PTAB section independently confirms zero AIA proceedings have ever been filed against US 10,543,179.
2. The petition bearing those three grounds — Argentum's ArgentumPharmaNovartisPharmaPet20779 — challenges claims 1–6 reciting "at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen", which is the claim language of the sister patent US 9,187,405, not the '179 claims (which recite VZV testing + vaccination). Ground 3's "Kappos 2010" reference is the NEJM TRANSFORMS publication of February 2010 — post-priority for the '179 patent but relied on there because the '405 petition took a different priority posture.

Those references remain useful comparative art for the '179's 0.5 mg dosing element, but they are not "cited against" the '179 patent and they carry no §315(e) estoppel here. Likewise, the "IPR Ex. 1006/1007/1008" exhibit designations belong to the '405 proceeding.

5. Recommended verification steps

1. Pull the verified Form PTO-892 / patent face for US 10,543,179 from USPTO Patent Center (application 15/986,992) to complete the U.S.-patent-documents column I could not fully retrieve here. Cross-check against the "References Cited" block of the issued PDF.
2. Confirm the exact identity and bibliographic details of "Berger 2009." The litigation record and the patent's own list both reference a Berger item about VZV vaccination before immunomodulatory therapy, but the same record also contains a "Berger 2010" (Ann Neurol 68(3):409–411). Distinguishing these is essential because only the pre-29-Sep-2009 Berger is § 102 art — and it is the single most important reference in the defendants' § 103 combination.
3. Confirm the publication date/authenticity of the "This Is MS" forum post (30 Apr 2009) before treating it as a §102(b) printed publication.
4. Do not rely on the post-2010 citations (Tyler 2015, Arvin 2015, VARIVAX/VARILRIX SmPCs, disease-modifying-therapy labels) as § 102 prior art unless the 2009 priority claim is successfully challenged — they are useful only as evidence of the state of the art in a priority/§112 (written description) challenge, which is exactly how the sibling '405 patent was invalidated.

Sources: Google Patents (https://patents.google.com/patent/US10543179/en); patent PDF cited-publications extract (https://patentimages.storage.googleapis.com/57/fe/21/91f6bb98e330a8/US10543179.pdf); Justia (https://patents.justia.com/patent/[10543179](/patent/10543179)); Argentum IPR petition (http://business.cch.com/ipld/ArgentumPharmaNovartisPharmaPet20779.pdf); D. Del. 1:20-cv-00133 D.I. 441 and D.I. 445 (https://storage.courtlistener.com/recap/gov.uscourts.ded.71311/); Orange Book / TheraRadar (https://theraradar.com/drugs/gilenya/patents/).

Obviousness Analysis — US 10543179 ("Dosage Regimen of an S1P Receptor Modulator")

1. Scope of the analysis and source of prior art

The Google Patents "References/Prior Art" listing was not reproduced in the fetched text, so the prior art below is drawn from the prosecution history, IPR petition, and district-court litigation records surfaced in search results (which I treat as the current ground truth per your instructions). The key references are confirmed in the file history and litigations of this patent:

• Garber, Nature Biotechnology 2008; 26(8):844–45 — identified by the Examiner during prosecution (Office Action of Nov. 16, 2018; Final OA of May 9, 2019). Discloses that a patient taking fingolimod died from chickenpox (varicella zoster virus, VZV).
• Kappos et al., N Engl J Med 2006; 355(11):1124–40 — Phase II oral fingolimod (FTY720) for relapsing MS (cited in the patent itself).
• Kappos 2005 (Ex. 1007 in the IPR) — Phase II MS trial of 1.25 mg and 5.0 mg daily fingolimod.
• "Kappos/Cohen 2010" — the Phase III TRANSFORMS publication relied on by defendants in Novartis v. HEC Pharm (D. Del. 1:20-cv-00133), disclosing that both 0.5 mg and 1.25 mg daily fingolimod reduced the annualized relapse rate in RRMS patients.
• Berger 2009 — discusses management of infection risk in MS patients on immunomodulatory drugs, expressly suggesting that "[i]f a substantial risk for reactivated varicella zoster exists with some of these treatments, one might argue that vaccination with the live virus varicella zoster virus vaccine be undertaken before the administration of that particular treatment."
• Harpaz 2008 (CDC/MMWR) — routine recommendations to identify VZV risk by asking patients about varicella (chickenpox) history or serologic testing, and routine varicella vaccination for persons ≥12 months without immunity.
• Schmouder et al., J. Clin. Pharmacol. 2006; 46:895 — fingolimod cardiac effects (cited in the patent).
• Budde (IPR Ex. 1008) — single-dose safety study in renal transplant patients; Chiba 1999 patent (IPR Ex. 1006) — fingolimod lymphocyte suppression.
• Arvin 2015 — Novartis's internal VZV study, published only in 2015 (i.e., not prior art).

The claims (as reported by DrugPatentWatch):

• Claim 1: A method for treating relapsing remitting multiple sclerosis (RRMS) in a patient in need thereof, comprising (a) identifying a patient at risk of contracting VZV infection by testing said patient for a history of VZV infection, (b) vaccinating the patient at risk of VZV infection, and (c) administering orally fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg, thereby limiting the risk of VZV infection.
• Claim 2: treating comprises reducing the frequency of clinical exacerbations.
• Claim 3: fingolimod administered as the hydrochloride salt.
• Claim 4: the infection is chickenpox.

2. Legal framework and the person of ordinary skill

Under 35 U.S.C. § 103 and Graham v. John Deere, obviousness is assessed from (1) the scope and content of the prior art; (2) differences between the prior art and the claims; (3) the level of ordinary skill; and (4) secondary considerations. A POSITA here would be a physician or clinical pharmacologist treating MS (or a clinical development scientist), familiar with fingolimod's Phase II/III program, S1P receptor modulator pharmacology, and standard infection-prevention practice for immunomodulatory therapies. The Examiner's rejection language reflects exactly this skill level: the combination of elements was characterized as "routine and basic common sense practices that take place in hospitals and clinics every day all over the world."

3. Prior-art combinations that would render claim 1 obvious

Combination A — Garber 2008 + routine medical practice / CDC guidance (Harpaz 2008) + known 0.5 mg fingolimod dosing (Kappos/Cohen 2010)

This is the combination the Examiner effectively advanced and the most straightforward § 103 case.

Element mapping:

Motivation to combine: Garber 2008 taught a concrete, life-threatening adverse event — a fingolimod patient died of chickenpox. The POSITA faced a known problem: fingolimod is lymphocyte-depleting and a fatal VZV infection had occurred in a treated patient. The solution — screen for VZV immunity and vaccinate seronegative patients before starting an immunosuppressive drug — was already the standard of care for other immunosuppressive/immunomodulatory therapies and was expressly recommended for MS patients on immunomodulators by Berger 2009 and by the CDC's routine varicella vaccination recommendations (Harpaz 2008). Combining a known drug dose (0.5 mg, shown effective in RRMS by Kappos/Cohen 2010) with a standard pre-treatment infection-screening/vaccination protocol yields the claimed method with a reasonable expectation of success. The Examiner made precisely this point: "the adverse effect of death from varicella zoster virus infection can be readily eliminated simply by making sure the patient, before starting fingolimod treatment, has either already had chicken pox, or has been properly vaccinated against the varicella zoster virus" (Final OA, May 9, 2019, at 9).

Combination B — Berger 2009 + Kappos/Cohen 2010 (or Kappos NEJM 2006) + Harpaz 2008

This is the combination the HEC defendants advanced in the Delaware litigation ("Kappos/Cohen + Berger + Harpaz"). Berger 2009 is the most potent single reference because it supplies an express suggestion of the exact solution — VZV vaccination before administration of an immunomodulatory drug — rather than merely describing the problem (as Garber does). Kappos/Cohen 2010 supplies the RRMS patient population and the 0.5 mg daily dose. Harpaz 2008 supplies the "identifying a patient at risk by testing history" step (asking about chickenpox history or serology). The POSITA would combine them because Berger 2009 explicitly points to vaccination as the management response where reactivation risk exists, and Harpaz 2008 gives the routine screening-and-vaccination algorithm for non-immune patients — a standard, predictable infection-prevention sequence.

Combination C — IPR Ground 2: Kappos 2005 + Budde + Chiba (for the 0.5 mg dose aspect)

The IPR petition's Ground 2 relied on Kappos 2005 (Phase II: 1.25 mg and 5.0 mg daily), Budde (single-dose safety in transplant), and Chiba 1999 (lymphocyte suppression with a broad dose range). While this combination is weaker on the specific 0.5 mg RRMS dose (the trial's lowest dose was 1.25 mg), a POSITA would still have been motivated to test a lower dose (0.5 mg) as a routine dose-optimization step for a chronic therapy with dose-related cardiac and infectious side effects — i.e., obvious dose-ranging of a known drug for a known condition, which is generally not patentable where the prior art provides a reason to select the lower dose (e.g., to reduce bradycardia and infection risk while preserving efficacy, later confirmed in the Phase III program).

4. Dependent claims

• Claim 2 ("reducing the frequency of clinical exacerbations"): disclosed by Kappos NEJM 2006 and Kappos/Cohen 2010 (annualized relapse rate reductions).
• Claim 3 (hydrochloride salt): fingolimod HCl is the standard pharmaceutical form disclosed throughout the fingolimod prior art and the patent's own description (FTY720 hydrochloride).
• Claim 4 (chickenpox): Garber 2008 specifically describes fatal chickenpox; "varicella zoster virus infection" and "chickenpox" are synonymous in this context (varicella = chickenpox), so the limitation adds nothing over claim 1.

5. Why a POSITA would combine — the motivation rationale

1. Known problem / known solution. The problem (VZV infection in an immunocompromised patient) and the solution (screening + live-vaccination before immunosuppression) were both known. Berger 2009 explicitly suggested vaccination before administration of immunomodulatory MS treatments; Harpaz 2008 codified the screening/vaccination routine for non-immune persons. This is a "predictable use of conventional techniques" (KSR).
2. Examiner's contemporaneous assessment. The Examiner rejected the claims twice as obvious over Garber plus common knowledge, finding the claimed steps "without question readily obvious" and "plain common sense" to medical practitioners — strong evidence of what a POSITA would have understood.
3. The 0.5 mg dose was already in the public domain. Kappos/Cohen 2010 disclosed that the 0.5 mg daily dose reduced the ARR in RRMS; the dose was not inventive, and the claimed method merely appends a standard infection-prevention step to a known dose.
4. No unexpected result shown. The patent identifies no data showing that vaccination was surprisingly effective, that 0.5 mg was unexpectedly safer, or that the combination produced an effect beyond the sum of its known parts. The specification's VZV discussion is aspirational rather than experimental.

6. Countervailing considerations (why the combination case is contested)

For balance, note the arguments Novartis successfully deployed in litigation and that created factual disputes on this exact combination:

• No established causal link before 2010. The only reported fingolimod/VZV death (Garber 2008; TRANSFORMS) was confounded by a higher 1.25 mg dose and high-dose corticosteroids; contemporary publications (Cohen 2010, Berger 2009, Garber 2008) expressly said it was impossible to conclude fingolimod contributed. Novartis's internal VZV study was not published until 2015 (Arvin 2015) — after the priority date.
• Possible teaching away. Novartis argued that a POSITA would not vaccinate with a live VZV vaccine in a patient about to receive an immunomodulator, for fear of vaccine-induced infection — i.e., the prior art could discourage the proactive vaccination step.
• Uncertainty about the 0.5 mg dose. As of the priority date, public knowledge of 0.5 mg efficacy in RRMS was incomplete relative to 1.25 mg (the Phase III result published in 2010); the IPR Ground 2 combination was correspondingly weaker because the lowest published Phase II dose was 1.25 mg.
• Secondary considerations. If demonstrated, long-felt need, unexpected results, or skepticism (e.g., differing Steering Committee opinions about implementing a VZV protocol after the TRANSFORMS death) could rebut a prima facie case.

7. Conclusion

The strongest § 103 case is Garber 2008 / Berger 2009 / Harpaz 2008 combined with Kappos/Cohen 2010 (or Kappos NEJM 2006): the prior art supplied (i) RRMS as the indication, (ii) 0.5 mg daily oral fingolimod as an effective dose, (iii) a documented fatal VZV event establishing the risk, (iv) an express suggestion to vaccinate before immunomodulatory therapy (Berger 2009), and (v) the routine screening-for-chickenpox-history/serology and vaccination algorithm (Harpaz 2008). A POSITA would have had ample motivation to combine these known elements with a reasonable expectation of success, and the Examiner's repeated obviousness rejections over Garber reflect that this is a straightforward application of conventional infection-prevention practice to a known drug and dose. The viability of the combination ultimately turns on the disputed factual questions of (a) whether the prior art established fingolimod-specific VZV risk sufficient to motivate the protocol, and (b) whether the prior art taught away from live vaccination in this setting — issues currently being litigated in Novartis v. HEC Pharm (D. Del. 1:20-cv-00133) and addressed in the IPR petition (Grounds 2–3).